Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Author:
Funder
Pfizer, Inc.
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/26/7/1421/16702816/mdv186.pdf
Reference31 articles.
1. Lung cancer: intragenic ERBB2 kinase mutations in tumours;Stephens;Nature,2004
2. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas;Shigematsu;Cancer Res,2005
3. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas;Arcila;Clin Cancer Res,2012
4. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014
5. Europe does it better: molecular testing across a national health care system-the French example;Nowak;Am Soc Clin Oncol Educ Book,2013
Cited by 244 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. HER2-targeted therapies in cancer: a systematic review;Biomarker Research;2024-02-02
2. Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis;Journal of Cancer Research and Clinical Oncology;2024-01-27
3. Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib;Pharmaceutics;2024-01-17
4. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells;Molecules;2024-01-04
5. Research Progress in Clinical Therapeutic Efficacy and Safety of HER2-Positive Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3